Professional
Added to YB: 2025-02-05
Pitch date: 2025-01-28
INDV [bullish]
Indivior Pharmaceuticals, Inc.
+173.78%
current return
Author Info
No bio for this author
Company Info
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Market Cap
$4.2B
Pitch Price
$12.28
Price Target
N/A
Dividend
N/A
EV/EBITDA
7.71
P/E
13.00
EV/Sales
3.41
Sector
Pharmaceuticals
Category
growth
Summers Value Partners Portfolio Holding: Indivior PLC
INDV: Long-acting opioid addiction drug Sublocade sales forecast cut due to Brixadi competition. Expect approval of improved dosing sNDA in Feb to level field. Long-acting agents underpenetrated at 5-6% of prescriptions. Bought at $7.74/share, 10x expected EPS.
Read full article (1 min)